{"name":"Polpharma Biologics S.A.","slug":"polpharma-biologics-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Intravenous (IV) infusions","genericName":"Intravenous (IV) infusions","slug":"intravenous-iv-infusions","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Intravenous (IV) infusions","genericName":"Intravenous (IV) infusions","slug":"intravenous-iv-infusions","phase":"phase_3","mechanism":"IV infusions are a delivery route for pharmaceutical agents administered directly into the bloodstream.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOZVl3RVlTMW9GcDlITlpsWGxESmc1ekNnMGZsZFVxNUx5dVByV2VLWTRvZlR5amtJbm5mYUYzM3Jfa1oyTjBnalhYTm9wSUxTTjFEQWppZXpNZDg4VUh5a1NUeC0zZ3A3ajNaWjdJX2ViRTFQZ3NXRnFXOEo0NF9keHMyX0ZlVldReWg2NExsSjJueWlMOWRMQ1Q1ZWxTU2dDLWFnbkZWUEs1OWxQajV3aDUyUlJlYnpoVklFMGNacWlONHZvVlBZQnF6TTRmQUpUaVdCNVNvQW5INm4zWkZ1eHJoRlVIRTJIdTMwbWF3Q1VUdlpuQm5V?oc=5","date":"2025-12-10","type":"patent","source":"Business Wire","summary":"Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases - Business Wire","headline":"Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPR0ZGbFpvckdUZjJjNTc5bG9GT0FGV1Z3eXlmblN2WFVIZ01IOE5TZjBWWFJFTHRnX01TM2s5eHFOQ1ltTmJJX1hEV0llLWpiRVIwRWlTT2xnOVZrV1RWTVRUUEk2aklFdWk4RHFtRVF0bzgwWFREdk9teURJSzVPQ0o3ZlBUcEtJYlRuUGp5NVhNanBPNl8xVXJVTUZBSjY5eXJxNy1fck12MmRIQ0Q5MmotWTYwb2RpTGJkNGxEdzhFdWJIaVk3OWxKRmRrdmtscVRza2x5cE52UXRWWWtoejRnV3BwdDNqVkZNUnFPRW9GMmwzRURmdWNuOUZ4anNsUEE?oc=5","date":"2025-11-17","type":"patent","source":"Business Wire","summary":"Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis - Business Wire","headline":"Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOa01ISEp0Zmg0ZkFpeEFMT0g2U1ZJS3Q4TURUOEQzRG5HajZNTkpDVEZvN0lFMWFHVzBKUmR2NTh6WVBVQTBaVG1leEVFZG1VbzNONWtucHpGV0ctR1FzeFM5bG04OUQ3RDREUlB2Vi1FOVRUMG81VGJ5NXZVUXMwd2JUNFUxY1E0TnB2aG81OWVsbWlwcGpR?oc=5","date":"2025-11-17","type":"pipeline","source":"Contract Pharma","summary":"Sandoz launches Tyruko in the U.S., Developed by Polpharma Biologics - Contract Pharma","headline":"Sandoz launches Tyruko in the U.S., Developed by Polpharma Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOUXFsZVZLeDcyZmE1S3ZBZzE1Sl9MWjB0T1BySEdtSUp6aG0wTVpVc2RMTU0taTZFYWxYSGpKT1lIMWI3VUxhaW1MQ0MxREFXMHpKM0l5bXZ1S3IzVmlvQ0k5RXEyTWVjaENtZ2dsdW14MFhtalp5WDFxOG14U1BTYmVGR0VFZ3JZMFR3NG5zeEdvZ3g2eDMxV1hvUEkyQnJHcXpiOXRrR1NvM0g3R0JwN1djMnpEMGJSVFBYUHBSdXItRk81cGRhYWUwcktNRDFuaXJCVXNrUVI1UkhfVjQxVHA2OU1BYTROWlc0QmZQY1FwRlZReW5nelNMQ0pROFBqVHdkRTFxM0ZrMHBFcUE?oc=5","date":"2025-10-20","type":"patent","source":"Business Wire","summary":"Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar - Business Wire","headline":"Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQbUV5TWJ2MkpGNTFOTjlsdUdjUUNCX1d4TEt6RWthb0l2SkZOZ2R2YmpuRmtDbV9hRVJvNlhETUhmRFg1djFmTTVwQTNiZUdpSXgtRFRPMEY0SmVIcnBQSGNBaDFyWG8wek5GbldtdWIzd2dyVUlJNGZuc1BTdGxVTmlGd2Q3aURDX0JaZjV3ajhpYmk1RlVaWjNyU3p2MFdyT19YaF9sZkZhaXdxdTNsRDl3?oc=5","date":"2025-09-02","type":"patent","source":"European Biotechnology Magazine","summary":"Polpharma Biologics secures distribution of upcoming biosimilars - European Biotechnology Magazine","headline":"Polpharma Biologics secures distribution of upcoming biosimilars","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxONlpCOGpYcjRKS0V0bmpNOE9kWXRiYlRhemhQSHdraF8yUVBaSGx2QWRGaVJ2bXRBOFRwa3F6MHpsUTlzTS1ieXRJSzBwcEZDNEVpOHBFLWpyTmhPZHprY2NCX1J3Z3RaWlNHWkZfRFRDbmozUWtwNDAzYnhuMTVPY0o4bzZaQjk1Sm1kdWtrVFEzX0Jpc2t4a3J3YXBLSWNRd240dmFSX3MzcGl2TzV3NUJQaWdsQjFCUW5hSktrVG5pYXNuMkdOcVlpeVRzZXYxSTM0dmdmcE1EeEtWWVM5aHhJSG1CRkVUcXg1cEI0Z3hwRGNZT2JqSmp6OGdhRHVSSXdwcGx6LWhxdHAwbTBYNU9mSnNsMWdQazlHMGhQZEQwRGZ5dFowblhIWkQ1MXZUbnYwLTgwck5PNFk?oc=5","date":"2025-09-02","type":"patent","source":"Via Ritzau","summary":"Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars - Via Ritzau","headline":"Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Gu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPVFdzNVhwLXE5UUZlZDdNMk81aGZ2eEJrd1Rnb0NmaVdHbURmTkhzNFg3RnIxYWVadWZFZ2NWaVpDTkxoWnhIVjdrSnRKLUtSejZ1THRuMWZ1QkpwY2ZydVdaaHh0V1NVdWk3WENHRVZrVHo4Sy0yd0thOEdvMWRZeUl4SkJjR3FsSWJQajN0eG9oVFNzWXhuN2dOZ3NxXzR1Y1Bhdi1meXRqUzI3UHEyUGY5N3dOVmpPSkNPbzhJWkhZWmJHLXJBcU1lX2VVNy0wRzhVZVRUWGhEekpmWGc?oc=5","date":"2025-08-05","type":"patent","source":"BioSpace","summary":"Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016 - BioSpace","headline":"Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}